Artivion (AORT) Expected to Announce Quarterly Earnings on Monday

Artivion (NYSE:AORT) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Monday, May 5th. Analysts expect Artivion to post earnings of $0.12 per share and revenue of $94.81 million for the quarter. Artivion has set its FY 2025 guidance at EPS.

Artivion (NYSE:AORT) last posted its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Price Performance

AORT stock opened at $23.36 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The business has a 50-day simple moving average of $23.95 and a two-hundred day simple moving average of $27.20. The company has a market capitalization of $997.22 million, a P/E ratio of -1,168.00 and a beta of 1.65. Artivion has a 52-week low of $20.98 and a 52-week high of $32.33.

Insider Buying and Selling

In related news, insider John E. Davis sold 6,457 shares of Artivion stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $176,340.67. Following the sale, the insider now owns 160,631 shares of the company’s stock, valued at approximately $4,386,832.61. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 42,156 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the transaction, the chief executive officer now directly owns 663,882 shares of the company’s stock, valued at approximately $18,130,617.42. This trade represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,799 shares of company stock worth $2,356,223. 7.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AORT. Needham & Company LLC cut their target price on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Stifel Nicolaus lowered their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Artivion presently has an average rating of “Buy” and an average target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.